XM does not provide services to residents of the United States of America.

U.S. states where recreational marijuana is legal



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>FACTBOX-U.S. states where recreational marijuana is legal</title></head><body>

Rewrites to focus on a potential move by the U.S. government to make marijuana use a less serious crime

April 30 (Reuters) -The U.S. Department of Justice is moving to make marijuana use a less serious crime, taking a step to reclassify the drug out of a category that includes heroin.

Reclassifying marijuana represents a first step toward narrowing the wide policy chasm between state and federal cannabis laws, with the drug legal in some form in nearly 40 states.

Currently, Marijuana falls under the same classification as heroin and LSD. A successful reclassification would include marijuana in the schedule three list alongside drugs such as Tylenol with codeine and ketamine.


Below is the list of U.S. states along with Washington DC that have legalized recreational marijuana:

State

Start of recreational cannabis Sales

Projected revenue in 2023**

Ohio

Effective end of 2024

N/A

Minnesota

Effective 2025

N/A

Virginia

Effective 2024

$198 million

Maryland

Effective July 2023

$477 million

Delaware

April 2023

$39 million

Missouri

February 2023

$1.56 billion

Connecticut

January 2023

$297 million

New York

December 2022

$391 million

Rhode Island

December 2022

$251 million

Vermont

October 2022

$212 million

Washington

July 2014

$1.20 billion

New Jersey

April 2022

$1.09 billion

New Mexico

April 2022

$650 million

Montana

January 2022

$346 million

Arizona

January 2021

$1.36 billion

Maine

October 2020

$413 million

Illinois

January 2020

$2 billion

Michigan

December 2019

$2.70 billion

Massachusetts

July 2018

$1.78 billion

California

January 2018

$4.90 billion

Nevada

July 2017

$867 million

Alaska

October 2016

$98 million

Oregon

October 2015

$941 million

Washington D.C.

July 2014

$1.20 billion

Colorado

January 2014

$1.60 billion

** Source - TD Cowen estimates from April 19



Reporting by Mrinalika Roy, Sourasis Bose in Bengaluru; Editing by Anil D'Silva and Shounak Dasgupta

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.